## **Core Concept**
The question revolves around the use of cytoprotective agents in the context of preventing xerostomia (dry mouth) in patients undergoing head and neck radiotherapy. Xerostomia is a common side effect of radiation therapy in this area, caused by damage to the salivary glands. Cytoprotective agents are used to protect normal tissues from the harmful effects of radiation.

## **Why the Correct Answer is Right**
The correct answer, **. Amifostine**, is a cytoprotective agent that has been used to reduce the incidence of xerostomia in patients undergoing post-operative radiation therapy for head and neck cancer. Amifostine works by protecting the salivary glands from radiation damage, thereby preserving their function. It is a prodrug that is activated in the body to its active thiol metabolite, which then scavenges free radicals and protects DNA from damage.

## **Why Each Wrong Option is Incorrect**
- **Option A:** is not commonly associated with the prevention of xerostomia in the context provided.
- **Option B:** does not directly relate to the prevention of xerostomia in head and neck radiotherapy patients.
- **Option D:** is not recognized for its role in preventing xerostomia in this specific clinical scenario.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that Amifostine is specifically used for its protective effects on the salivary glands during head and neck radiation therapy, making it a valuable agent in reducing the incidence of xerostomia. This is a high-yield fact for exams and clinical practice.

## **Correct Answer Line**
**Correct Answer: C. Amifostine**